Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma

Next Previous
X
Search
Trial Profile

An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bizaxofusp (Primary) ; Bizaxofusp (Primary) ; Bevacizumab
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors Medicenna Therapeutics

    • Most Recent Events

    • 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 24 Apr 2024 According to a Medicenna Therapeutics media release, data from this study will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held in Chicago from May 31 -June 4, 2024
    • 14 Feb 2024 According to a Medicenna Therapeutics media release, the company plans to seek to apply for Breakthrough Therapy Designation (BTD) for bizaxofusp based on compelling data from this trial presented at the SNO.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top